Charles Retina Institute

Summary

Charles Retina Institute is a medical facility located in Germantown, Tennessee. This center is recognized for care of Macular Degeneration, Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Disease, None and other specialties. Charles Retina Institute is involved with conducting 43 clinical trials across 33 conditions. There are 2 research doctors associated with this hospital, such as Stephen Huddleston, MD and Stephan Huddleston, MD.

Top PIs

Clinical Trials running at Charles Retina Institute

Age-Related Macular Degeneration

Macular Degeneration

Retinal Disease

Choroidal Neovascularization

Retinal Degeneration

None

Choroidal neovascularization

Wet AMD

Diabetic Macular Edema

Glaucoma

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.

Recruiting

2 awards

Phase 3

2 criteria

PDS Implant with Ranibizumab

for Age-Related Macular Degeneration

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Recruiting

2 awards

Phase 3

3 criteria

RGX-314 Gene Therapy

for Wet Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.

Recruiting

1 award

Phase 2 & 3

6 criteria